You probably don’t want to hear your doctor proclaiming “I’m so indie, I was prescribing that *way* before it was cool.” Or maybe you do? If you’re a hipster and you really need to know when a particular band stops being underground and teeters on the edge of being mainstream so you can only like … Continue reading How long does it take for new prescription drugs to become mainstream?
So #hic12 is nearly here and I’ll be there in a rather unusual capacity. I won’t be giving a talk. I won’t even be standing in front of a poster. I’ll be there as the official twitterer, which means I’ll be flitting around from talk to talk, tweeting from the official @hic_2012 account, and hopefully connecting people … Continue reading The Health Informatics Conference 2012, Sydney
Learning a new programming language is hard. But learning about learning a new language probably makes it easier. I’m going to admit that my coder upbringing was a little bit unusual, perhaps because of timing. It might also have something to do with the fact that when I was an undergraduate, I was doing units … Continue reading Learning new languages
Alongside colleagues (Enrico Coiera and Richard Day) from here in Sydney and (Kenneth Mandl) from near Boston in the US, I wrote an article for Science Translational Medicine in which we related the current system of “clinical trial evidence translation” to the very successful open source software movement. We highlighted the factors in that success - … Continue reading Learning from “Learning from Hackers”
Below is a copy of an article I wrote for The Conversation. It’s an independent source of information and analysis about things that matter - but from the university and research perspective, which means it’s generally more rigorous than much of the rest. This article was originally published at The Conversation. Read the original article. TRANSPARENCY … Continue reading Repost: Pharma’s influence over published clinical evidence
Last week the US Food and Drug Administration released new warnings about the use of statins for patients in the United States. The warnings that have been added to labels in the US come from worries about liver injury, memory-loss and confusion, increased blood sugar levels and some new potentially dangerous interactions between one statin … Continue reading Who creates the clinical evidence for cholesterol-lowering drugs?